Literature DB >> 32954446

Differences in Liver Parenchyma are Measurable with CT Radiomics at Initial Colon Resection in Patients that Develop Hepatic Metastases from Stage II/III Colon Cancer.

John M Creasy1, Kristen M Cunanan2, Jayasree Chakraborty1, John C McAuliffe1, Joanne Chou2, Mithat Gonen2, Victoria S Kingham1, Martin R Weiser1, Vinod P Balachandran1, Jeffrey A Drebin1, T Peter Kingham1, William R Jarnagin1, Michael I D'Angelica1, Richard K G Do3, Amber L Simpson4,5.   

Abstract

BACKGROUND: Currently, there are no methods to identify patients with an increased risk of liver metastases to guide patient selection for liver-directed therapies. We tried to determine whether quantitative image features (radiomics) of the liver obtained from preoperative staging CT scans at the time of initial colon resection differ in patients that subsequently develop liver metastases, extrahepatic metastases, or demonstrate prolonged disease-free survival.
METHODS: Patients who underwent resection of stage II/III colon cancer from 2004 to 2012 with available preoperative CT scans were included in this single-institution, retrospective case-control study. Patients were grouped by initial recurrence patterns: liver recurrence, extrahepatic recurrence, or no evidence of disease at 5 years. Radiomic features of the liver parenchyma extracted from CT images were compared across groups.
RESULTS: The cohort consisted of 120 patients divided evenly between three recurrence groups, with an equal number of stage II and III patients in each group. After adjusting for multiple comparisons, 44 of 254 (17%) imaging features displayed different distributions across the three patient groups (p < 0.05), with the clearest distinction between those with liver recurrence and no evidence of disease. Increased heterogeneity in the liver parenchyma by radiomic analysis was protective of liver metastases.
CONCLUSIONS: CT radiomics is a promising tool to identify patients at high risk of developing liver metastases and is worthy of further investigation and validation.

Entities:  

Mesh:

Year:  2020        PMID: 32954446      PMCID: PMC7940539          DOI: 10.1245/s10434-020-09134-w

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  26 in total

1.  Variations in Metastasis Site by Primary Location in Colon Cancer.

Authors:  Ramzi Amri; Liliana G Bordeianou; Patricia Sylla; David L Berger
Journal:  J Gastrointest Surg       Date:  2015-05-02       Impact factor: 3.452

2.  Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.

Authors:  Leigh Casadaban; Garth Rauscher; Mebea Aklilu; Dana Villenes; Sally Freels; Ajay V Maker
Journal:  Cancer       Date:  2016-07-15       Impact factor: 6.860

3.  Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis.

Authors:  Jian Zheng; Jayasree Chakraborty; William C Chapman; Scott Gerst; Mithat Gonen; Linda M Pak; William R Jarnagin; Ronald P DeMatteo; Richard K G Do; Amber L Simpson
Journal:  J Am Coll Surg       Date:  2017-09-21       Impact factor: 6.113

4.  Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial.

Authors:  Siân A Pugh; Bethany Shinkins; Alice Fuller; Jane Mellor; David Mant; John N Primrose
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

5.  Epidemiology and management of liver metastases from colorectal cancer.

Authors:  Sylvain Manfredi; Côme Lepage; Cyril Hatem; Olivier Coatmeur; Jean Faivre; Anne-Marie Bouvier
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

6.  Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.

Authors:  Erin S O'Connor; David Yu Greenblatt; Noelle K LoConte; Ronald E Gangnon; Jinn-Ing Liou; Charles P Heise; Maureen A Smith
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

7.  Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival.

Authors:  Frank Benedix; Rainer Kube; Frank Meyer; Uwe Schmidt; Ingo Gastinger; Hans Lippert
Journal:  Dis Colon Rectum       Date:  2010-01       Impact factor: 4.585

Review 8.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.

Authors:  Sotaro Sadahiro; Toshiyuki Suzuki; Kenji Ishikawa; Seiei Yasuda; Tomoo Tajima; Hiroyasu Makuuchi; Takuro Saitoh; Chieko Murayama
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

10.  Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

Authors:  Manish A Shah; Lindsay A Renfro; Carmen J Allegra; Thierry André; Aimery de Gramont; Hans-Joachim Schmoll; Daniel G Haller; Steven R Alberts; Greg Yothers; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

View more
  6 in total

1.  Machine learning radiomics can predict early liver recurrence after resection of intrahepatic cholangiocarcinoma.

Authors:  Joshua S Jolissaint; Tiegong Wang; Kevin C Soares; Joanne F Chou; Mithat Gönen; Linda M Pak; Thomas Boerner; Richard K G Do; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; T P Kingham; Alice C Wei; William R Jarnagin; Jayasree Chakraborty
Journal:  HPB (Oxford)       Date:  2022-02-17       Impact factor: 3.842

Review 2.  Predicting cancer outcomes with radiomics and artificial intelligence in radiology.

Authors:  Kaustav Bera; Nathaniel Braman; Amit Gupta; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Nat Rev Clin Oncol       Date:  2021-10-18       Impact factor: 65.011

3.  Current challenges in metastasis research and future innovation for clinical translation.

Authors:  Amelia L Parker; Madeleine Benguigui; Jaime Fornetti; Erica Goddard; Serena Lucotti; Jacob Insua-Rodríguez; Adrian P Wiegmans
Journal:  Clin Exp Metastasis       Date:  2022-01-24       Impact factor: 5.150

4.  Radiomics artificial intelligence modelling for prediction of local control for colorectal liver metastases treated with radiotherapy.

Authors:  Ricky Hu; Ishita Chen; Jacob Peoples; Jean-Paul Salameh; Mithat Gönen; Paul B Romesser; Amber L Simpson; Marsha Reyngold
Journal:  Phys Imaging Radiat Oncol       Date:  2022-09-13

Review 5.  The Hepatic Pre-Metastatic Niche.

Authors:  Benjamin Ormseth; Amblessed Onuma; Hongji Zhang; Allan Tsung
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

6.  Contrast Administration Impacts CT-Based Radiomics of Colorectal Liver Metastases and Non-Tumoral Liver Parenchyma Revealing the "Radiological" Tumour Microenvironment.

Authors:  Francesco Fiz; Guido Costa; Nicolò Gennaro; Ludovico la Bella; Alexandra Boichuk; Martina Sollini; Letterio S Politi; Luca Balzarini; Guido Torzilli; Arturo Chiti; Luca Viganò
Journal:  Diagnostics (Basel)       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.